{"id":10100,"date":"2026-04-01T06:13:37","date_gmt":"2026-04-01T11:13:37","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10100"},"modified":"2026-04-01T06:17:26","modified_gmt":"2026-04-01T11:17:26","slug":"nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","title":{"rendered":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u0639\u064a\u0651\u0646 \u0628\u0648\u0644 \u0647\u0627\u0644\u064a\u0646\u060c \u0627\u0644\u062e\u0628\u064a\u0631 \u0627\u0644\u0645\u062e\u0636\u0631\u0645 \u0641\u064a \u0635\u0646\u0627\u0639\u0629 \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646\u060c \u0641\u064a \u0645\u0646\u0635\u0628 \u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644\u0644\u0639\u0645\u0644\u064a\u0627\u062a \u0644\u062a\u0639\u0632\u064a\u0632 \u0627\u0644\u062c\u0627\u0647\u0632\u064a\u0629 \u0627\u0644\u062a\u062c\u0627\u0631\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Veteran\u00a0ophthalmology executive with over 30 years of experience spanning R&D, manufacturing, quality, commercial strategy, and franchise leadership<\/em><\/h3>

\u0646\u0627\u0626\u0628 \u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u0633\u0627\u0628\u0642 \u0648\u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u0639\u0627\u0644\u0645\u064a \u0644\u0642\u0633\u0645 \u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0639\u064a\u0646 \u0641\u064a \u0634\u0631\u0643\u0629 \u0623\u0644\u0643\u0648\u0646\u060c \u064a\u062a\u0645\u062a\u0639 \u0628\u062e\u0628\u0631\u0629 \u0648\u0627\u0633\u0639\u0629 \u0641\u064a \u0628\u0646\u0627\u0621 \u0648\u062a\u0648\u0633\u064a\u0639 \u0646\u0637\u0627\u0642 \u0627\u0644\u0639\u0644\u0627\u0645\u0627\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629 \u0641\u064a \u0645\u062c\u0627\u0644 \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646.<\/em><\/h3>

\u064a\u0639\u0632\u0632 \u0647\u0630\u0627 \u0627\u0644\u062a\u0639\u064a\u064a\u0646 \u0627\u0644\u0642\u064a\u0627\u062f\u0629 \u0627\u0644\u062a\u0634\u063a\u064a\u0644\u064a\u0629 \u0645\u0639 \u062a\u0642\u062f\u0645 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0641\u064a \u062a\u0637\u0648\u064a\u0631 MCO-010 (MOGENRY\u2122) \u0646\u062d\u0648 \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0648\u0625\u0645\u0643\u0627\u0646\u064a\u0629 \u062a\u0633\u0648\u064a\u0642\u0647 \u062a\u062c\u0627\u0631\u064a\u0627\u064b<\/em><\/h3>

\u062f\u0627\u0644\u0627\u0633<\/span>,\u00a01 \u0623\u0628\u0631\u064a\u0644 2026<\/span>\u00a0 \u2014 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>, \u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629\u060c \u0627\u0644\u0645\u0644\u062a\u0632\u0645\u0629 \u0628\u062a\u0637\u0648\u064a\u0631 \u0648\u062a\u0633\u0648\u064a\u0642 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u062f\u064a\u062f\u0629 \u0644\u0627 \u062a\u0631\u062a\u0628\u0637 \u0628\u0645\u0631\u0636 \u0645\u0639\u064a\u0646 \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u0636\u0648\u0621 \u0648\u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0628\u0633\u0628\u0628 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0627\u0644\u064a\u0648\u0645 \u0639\u0646 \u062a\u0639\u064a\u064a\u0646 \u0628\u0648\u0644 \u0647\u0627\u0644\u064a\u0646 \u0641\u064a \u0645\u0646\u0635\u0628 \u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644\u0644\u0639\u0645\u0644\u064a\u0627\u062a.<\/p>

Mr. Hallen brings over 30 years of broad ophthalmic leadership experience spanning marketing, sales, manufacturing, quality, research and development, and business strategy. He previously served as Vice President and Global Head of Retina at Alcon, where he helped lead one of the industry’s premier retina franchises, and also held a Vice President of R&D role supporting internal development and external acquisition activities across Alcon’s business units. Mr. Hallen also served as a board member of US Retina.<\/p>

As Chief Operating Officer, Mr. Hallen will lead Nanoscope’s global operations, including commercial readiness, supply chain, and cross-functional execution, as the company advances MCO-010 (MOGENRY\u2122) toward potential regulatory approval and launch.<\/p>

“Paul is a highly respected ophthalmology leader with a rare combination of technical, operational, and commercial expertise,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. “We have known and closely interacted with Paul for many years, and his appointment comes at an important time as we continue preparing for the potential commercialization of MOGENRY. His experience across retina, product development, and global launch planning will be invaluable as we work to bring our vision-restoring therapies to patients worldwide.”<\/p>

“I am excited to join Nanoscope at such an important stage in its development,” said Paul Hallen, Chief Operating Officer of Nanoscope Therapeutics. “Nanoscope’s MOGENRY platform represents a fundamentally differentiated approach with the potential to restore vision for patients with severe retinal disease. I look forward to working with the team to help advance MOGENRY toward potential approval and to support the company’s operational and commercial readiness for the next stage of growth.”<\/p>

\u0627\u0644\u062a\u0642\u062f\u0645 \u0646\u062d\u0648 \u0627\u0644\u062a\u0633\u0648\u064a\u0642
<\/b>Nanoscope continues to build clinical, regulatory, and scaled-up manufacturing momentum in support of MOGENRY for retinitis pigmentosa, including advancement of its rolling Biologics License Application in the United States. The company has also established a growing global regulatory foundation for MOGENRY, with Orphan Drug, Fast Track, and RMAT designations in the United States, Sakigake and Orphan Drug designations in Japan, five EMA Orphan designations across inherited retinal dystrophies, and, most recently, an Orphan drug designation for IRDs in Saudi Arabia. These milestones reflect the company’s expanding international regulatory pathway as it advances commercialization planning across key global markets.<\/p>

\u062d\u0648\u0644 \u0645\u0646\u0635\u0629 \u0625\u062f\u0627\u0631\u0629 \u0623\u0648\u0627\u0645\u0631 \u0627\u0644\u0642\u064a\u0627\u062f\u0629
<\/b>MCO \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u0645\u0646\u0635\u0629 \u0639\u0644\u0627\u062c\u064a\u0629 \u062a\u064f\u0639\u0637\u0649 \u0644\u0645\u0631\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629\u060c \u0648\u062a\u064f\u062d\u0642\u0646 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u0647\u064a \u0645\u0635\u0645\u0645\u0629 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u062a\u0646\u0643\u0633 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) \u0648\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD) \u0648\u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA). \u062a\u0639\u0645\u0644 MCO \u0639\u0644\u0649 \u062a\u0646\u0634\u064a\u0637 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u062b\u0646\u0627\u0626\u064a\u0629 \u0627\u0644\u0642\u0637\u0628 \u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0643\u062b\u0627\u0641\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0644\u062a\u0635\u0628\u062d \u062d\u0633\u0627\u0633\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0645\u0633\u062a\u0641\u064a\u062f\u0629\u064b \u0645\u0646 \u0627\u0644\u062f\u0648\u0627\u0626\u0631 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0645\u062a\u0628\u0642\u064a\u0629 \u0628\u0639\u062f \u0645\u0648\u062a \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621. \u0644\u0627 \u064a\u062a\u0637\u0644\u0628 \u0639\u0644\u0627\u062c MCO \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0623\u0648 \u062c\u0631\u0627\u062d\u0629 \u063a\u0627\u0632\u064a\u0629 \u0623\u0648 \u062c\u0631\u0639\u0627\u062a \u0645\u062a\u0643\u0631\u0631\u0629\u060c \u0645\u0645\u0627 \u064a\u062a\u064a\u062d \u062a\u0637\u0628\u064a\u0642\u0647 \u0639\u0644\u0649 \u0646\u0637\u0627\u0642 \u0648\u0627\u0633\u0639 \u0645\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0636\u0645\u0646 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0641\u064a \u0639\u064a\u0627\u062f\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629.<\/p>

\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633
<\/b>\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c \u0628\u0635\u0631\u064a \u0648\u0631\u0627\u062b\u064a \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0646\u0648\u0639 \u0627\u0644\u0645\u0631\u0636\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0630\u0644\u0643 \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0627\u0644\u062a\u064a \u062d\u0642\u0642\u062a\u0647\u0627 \u062a\u062c\u0631\u0628\u0629 RESTORE \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0627\u0644\u0645\u0636\u0628\u0648\u0637\u0629 \u0628\u0627\u0644\u063a\u0641\u0644\u060c \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2\u0628\/3\u060c \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) (NCT04945772<\/a>\u0628\u062f\u0623\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA). \u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629\u060c \u064a\u064f\u062d\u062a\u0645\u0644 \u0623\u0646 \u064a\u0635\u0628\u062d MCO-010 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP)\u060c \u062d\u064a\u062b \u064a\u064f\u0639\u0637\u0649 \u0643\u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629 \u062f\u0648\u0646 \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629. \u0643\u0645\u0627 \u0623\u0638\u0647\u0631\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0646\u062a\u0627\u0626\u062c \u0648\u0627\u0639\u062f\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0640 MCO-010 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).NCT05417126<\/a>) \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621\u00a0\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629<\/a>\u00a0\u0641\u064a \u0623\u0648\u0627\u0626\u0644 \u0639\u0627\u0645 2026\u060c \u062d\u0635\u0644 \u062f\u0648\u0627\u0621 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0643\u0644 \u0645\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP) \u0648\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 (SD)\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 RMAT \u0644\u0645\u0631\u0636 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u062a\u0635\u0646\u064a\u0641\u0627\u062a \u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0648\u0643\u0627\u0644\u0629 \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0623\u0648\u0631\u0648\u0628\u064a\u0629 (EMA) \u0644\u062a\u063a\u0637\u064a\u0629 \u0636\u0645\u0648\u0631 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u063a\u064a\u0631 \u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0648\u0627\u0644\u0645\u062a\u0644\u0627\u0632\u0645\u064a \u0627\u0644\u0630\u064a \u064a\u0647\u064a\u0645\u0646 \u0641\u064a\u0647 \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0639\u0635\u0648\u064a\u0629 \u0648\u0627\u0644\u0645\u062e\u0631\u0648\u0637\u064a\u0629\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0627\u0644\u0635\u0641\u0631\u0627\u0621. \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u0646 \u064a\u0628\u062f\u0623 \u0628\u0631\u0646\u0627\u0645\u062c \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u062f\u0648\u0627\u0621 MCO \u0641\u064a \u0639\u0644\u0627\u062c \u0627\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA) \u0641\u064a \u0623\u0648\u0627\u0626\u0644 \u0639\u0627\u0645 2026. \u0648\u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0627\u0644\u0623\u062e\u0631\u0649 \u0627\u0644\u062c\u0627\u0647\u0632\u0629 \u0644\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u062c\u062f\u064a\u062f\u0629 (IND) \u0639\u0644\u0627\u062c \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631 (LCA).<\/p>

\u0627\u062a\u0635\u0627\u0644:
<\/b>\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u064a\u0643\u0633
+1 (817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Veteran\u00a0ophthalmology executive with over 30 years of experience spanning R&D, manufacturing, quality, commercial strategy, and franchise leadership Former Vice President and Global Head of Retina at Alcon, with deep experience building and scaling global ophthalmic franchises Appointment strengthens operational leadership as Nanoscope advances MCO-010 (MOGENRY\u2122) toward BLA submission and potential commercialization DALLAS,\u00a0April 1, 2026\u00a0 — […]<\/p>\n","protected":false},"author":1,"featured_media":10101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T11:13:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T11:17:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u0639\u064a\u0651\u0646 \u0628\u0648\u0644 \u0647\u0627\u0644\u064a\u0646\u060c \u0627\u0644\u062e\u0628\u064a\u0631 \u0627\u0644\u0645\u062e\u0636\u0631\u0645 \u0641\u064a \u0645\u062c\u0627\u0644 \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646\u060c \u0641\u064a \u0645\u0646\u0635\u0628 \u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644\u0644\u0639\u0645\u0644\u064a\u0627\u062a \u0644\u062a\u0639\u0632\u064a\u0632 \u062c\u0627\u0647\u0632\u064a\u0629 \u0627\u0644\u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u062c\u0627\u0631\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629.","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-04-01T11:13:37+00:00","article_modified_time":"2026-04-01T11:17:26+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Wilson PJ","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"4 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"wordCount":733,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","url":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u062a\u0639\u064a\u0651\u0646 \u0628\u0648\u0644 \u0647\u0627\u0644\u064a\u0646\u060c \u0627\u0644\u062e\u0628\u064a\u0631 \u0627\u0644\u0645\u062e\u0636\u0631\u0645 \u0641\u064a \u0645\u062c\u0627\u0644 \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646\u060c \u0641\u064a \u0645\u0646\u0635\u0628 \u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644\u0644\u0639\u0645\u0644\u064a\u0627\u062a \u0644\u062a\u0639\u0632\u064a\u0632 \u062c\u0627\u0647\u0632\u064a\u0629 \u0627\u0644\u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u062c\u0627\u0631\u064a\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064a\u0629.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u0648\u064a\u0644\u0633\u0648\u0646 \u0628\u064a \u062c\u064a\u0647"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=10100"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10100\/revisions"}],"predecessor-version":[{"id":10105,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/10100\/revisions\/10105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/10101"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=10100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=10100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=10100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}